7 ms·
High cost of cancer care in the U.S. doesn’t reduce mortality rates
- xqcgrek2 4y agoNot mentioned: the US research complex and healthcare spending subsidizing development of state-of-the-art therapies for other countries. They don't bear the cost so expecting the US to do better at same or lower cost is structually impossible.
- cjbenedikt 4y agoDo you have any data to backup your claim? For example Cuban healthcare/treatment/outcome is excellent based on its own research. Roche(Swiss) nor Merck ( German, not related to US Merck) don't benefit much (if at all) from US subsidies.
- ch4s3 4y agoCuba has developed a few drugs and exports doctors as chattel for foreign income but their actual healthcare is abysmal. They larger operate without antibiotics, pain killers, and at times clean water. They can’t provide 24h power to hospitals so most modern tech is pointless there. The notion that anything else is true is just Cuban propaganda. There are tons of accounts from NGOs and doctors who have defected.
- mjewkes 4y ago>Do you have any data to backup your claim? I would suggest The Great American Drug Deal, by Peter Kolchinsky. Also - https://www.rand.org/pubs/research_briefs/RB9412.html https://www.rand.org/pubs/research_briefs/RB9412.html >For example Cuban healthcare/treatment/outcome is excellent based on its own research Cuba does not contribute substantially to global pharmaceutical research. >Roche(Swiss) nor Merck ( German, not related to US Merck) don't benefit much (if at all) from US subsidies. Roche makes 55% of its revenue from US drug sales (https://assets.cwp.roche.com/f/126832/x/db9d31e8a7/fb20e.pdf https://assets.cwp.roche.com/f/126832/x/db9d31e8a7/fb20e.pdf p22) EMD Serono (formerly Merck KgAA) is similar. These revenues are the topline driver of the drug development industry.
- lr4444lr 4y agoCuba's data is pretty suspect. Too lazy to find it at the moment, but I recall reading that their cancer rates or deaths were some absurd fraction of what would be expected given smoking rates even compared with better developed countries. They also had some eye raising way of counting perinatal infant death that makes their infant mortality rates look a lot lower.
- biorach 4y agoYou'd really need to show some numbers to back this up. Is the cost of funding the "research complex" included in the expenditure on health care? At least some of this cost is born by the Federal government, foundations etc, is this counted as general health care expenditure (I doubt it) Some of the research is funded by companies - since they sell globally this funding cannot be counted as purely of US origin. Other countries also have significant health research - e.g. UK, France, Germany - your point would also apply to them. Overall your point is dubious, and vague - you'd need to present some solid numbers to back it up.
- mjewkes 4y agoHey biorach - I would suggest: https://www.rand.org/pubs/research_briefs/RB9412.html https://www.rand.org/pubs/research_briefs/RB9412.html and The Great American Drug Deal, by Peter Kolchinsky. Specific claims: - The US pays more for new drugs than the rest of the world - The US contribution is disproportionate, and is major driver of the drug development industry. -If the US paid less for new drugs, the entire industry would slow, and we would have fewer more effective treatments. ... Routine medical procedures being crazy expensive is unrelated and pathological.
- raverbashing 4y agoYou're assuming that most of the "extra" money goes back in research and not to shareholders and management bonuses Given how pharma companies operate, I kinda doubt it.
- mjewkes 4y agoNo assumptions. The rand article addresses that directly.
- awinter-py 4y agoon the research side, this would tend to reduce prices, right? clinical trials usually aren't charging (per [1]). this 2017 article[2] claims that the US pharma $ premium is more than R&D spending for 13 of 15 top pharma cos. (Note: this isn't even talking about profit, it's talking about the excess profit from higher US prices). Maybe you can make an argument that R&D is lockstep to margins, and would shrink if margins went down? 1. https://www.hhs.gov/ohrp/sachrp-committee/recommendations/november-20-2019-attachment-a/index.html https://www.hhs.gov/ohrp/sachrp-committee/recommendations/no... 2. https://www.healthaffairs.org/do/10.1377/forefront.20170307.059036/ https://www.healthaffairs.org/do/10.1377/forefront.20170307....
- byecancer21 4y agoThis mirrors my personal experience. To make a treatment decision, against the advice of my local doctors, that was key to survival I relied on US research. To compare costs: For an extremely rare cancer, total cost of treatment was 100k EUR in Germany, whereas US patients report case costs of >2m USD. Part of these savings stem from the public healthcare system not providing adequate treatment, while strictly necessary for a reasonable chance of survival in this case. What happens in Germany then is the amazing doctors do stuff anyway (if you can convince them), bill whatever they can, and write off the remainder. Profits from privately insured patients make up for this shortfall here. Public healthcare being adequate is somewhat of a myth, for Germany at least.
- rr808 4y agoI kinda feel that with American's terrible diet and lack of exercise, matching other countries' mortality shows actually a pretty good medical system.
- jphoward 4y agoBut this is adjusting for the baseline illness, remember. This isn't just age-standardised mortality rates. It's disease-standardised mortality. Hopefully they've adjusted for confounders...
- asdff 4y agoYeah, because people would rather go bankrupt than die. Doesn't make it a good system.
- salt-thrower 4y agoVery true. The headline is misleading though. The actual article is framed as the inverse: "does spending more on cancer care give the US better outcomes?" and the answer is no. We're on par with other wealthy countries that spend half as much per person on cancer care. So yeah, the exorbitant costs of US healthcare do not correlate with better health outcomes. Just worse financial outcomes.
- deleted 4y ago[deleted]
- freediver 4y agoThe relatively poor average quality of healthcare was made apparent in covid pandemic where US had among the highest mortality rates and deaths per capita in the developed world [1] And I do not need data to tell me this, just overal experience comparing it to my previous experience getting healthcare in Europe leaves a lot to be desired. Getting medical care in US is hard with a lot of bureaucratic/insurance overhead and when you finally get to the doctor they are more prone to follow strict procedures/checklists to reduce liability instead of being genuinly curious about your condition. And all this while most have to pay astronomical price for healthcare out of their pocket. Not sure that the case for privatised healthcare can hold up with these results. [1] https://coronavirus.jhu.edu/data/mortality https://coronavirus.jhu.edu/data/mortality
- jjeaff 4y agoWhile your premise may not be wrong, I'm not so sure that COVID statistics can tell us much between countries. There are a great deal of countries that are either wholly inadequate, or purposefully misleading when it comes to their true COVID numbers. For example, India has an official COVID death count of around 500k. The WHO has made their own estimates and believe their death count to be closer to 5 million, ten times the official number.
- blipvert 4y agoIs the best response that you have is to say “We probably better than an underdeveloped country like India”? Talk about damned by faint praise …
- kwhitefoot 4y agoThe thing to look at is the excess death rate.
- dennis_jeeves1 4y agoWhich does not seemed to changed. Of course the they did put a spin on it by saying that the flu and other diseases disappeared because of all the measures taken. Heads I win, tails you loose.
- david_l_lin 4y ago> Findings of this study suggest that the US expenditure on cancer care may not be commensurate with improved cancer outcomes. Well yeah, the cost of healthcare in the US is astronomical. https://www.healthsystemtracker.org/chart-collection/health-spending-u-s-compare-countries-2/ https://www.healthsystemtracker.org/chart-collection/health-... This would be the same across diseases, not just cancer.
- pessimizer 4y agoSince we spend twice as much as anyone else on healthcare but rank somewhere around 50th in lifespan, it would be weird if we were getting better outcomes in any area due to greater spending.
- kurupt213 4y agoThe average lifespan numbers are rigged. Most countries don’t count an infant delivered alive but terminal in their infant mortality numbers. Like when a placenta ruptures and you have an emergency birth before 28 or 30 weeks. Those don’t count in most if not all of Europe. In the US, every live birth counts, even if it only lasts minutes I don’t know if that completely makes up the difference, but the real disparity is nowhere near the numbers that get thrown around. It’s apples vs oranges. Covid positives were a similar situation. Most countries would not report a positive Covid patient unless the test was positive and the patient was symptomatic.
- dpierce9 4y agoData collection differences are well-known to the people who produce cross-country numbers. Further, your specific observation about when births are counted in the US is flat wrong. We have 54 ways of doing things. Furthermore, not everything is a conspiracy. Reasonable people do things differently. To suggest these numbers are rigged is glib.
- LodeOfCode 4y ago>I don’t know if that completely makes up the difference, but the real disparity is nowhere near the numbers that get thrown around. It’s apples vs oranges. The CDC[2020] reports an infant mortality rate of <0.6%. Excluding all of it would only increase life expectancy from 78.8 to 79.2 [2020]https://www.cdc.gov/nchs/products/databriefs/db395.htm https://www.cdc.gov/nchs/products/databriefs/db395.htm
- SoftTalker 4y ago> “The pattern of spending more and getting less is well-documented in the U.S. healthcare system; now we see it in cancer care, too,” said co-author Elizabeth Bradley It's a cynical viewpoint, but I can forgive those who think that modern health care is mostly a way to extract as much wealth as possible from sick people before they die.
- frogperson 4y agoHaving dealt with end of life Healthcare for a family member who dies of cancer, I'm curious how you can see it any other way. It is purely wealth extraction at end of life. When you lose you job and insurance due to health, you can not qualify for state aid if you have any assets at all. you you must spend until you are broke before you get any help. Then there is the issue of nursing homes. If you end up in one, they have the ability to unwind any asset transfers in the previous 5 years, so if you thought you can transfer your house to your children before you die, you can not. The nursing home and the hospitals will suck every penny out of an estate and the only way to prevent it is to die quickly.
- nextos 4y agoAs a researcher in the field and someone who has seen a few friends go due to cancer, the current standard of care is very frustrating. I believe cancer is orders of magnitude easier to treat when it is still asymptomatic but detectable using metrics such as circulating tumor DNA (ctDNA). However, it is taking ages to deploy this technology because healthcare struggles with any data-oriented solution.
- david_l_lin 4y agoHealthcare is notoriously slow with adoption of new technology. IMO this is because healthcare is fee-for-service, which is basically incompatible with prevention. A movement to value-based care would vastly improve adoption of preventive and personalized healthcare.
- lordgrenville 4y agoThe HMO model was basically designed to bring in an element of value-based reimbursement. For example, the CMS capitation payments to Medicare Advantage plans are weighted by (inter alia) health outcomes.
- wtch98 4y agoOK that explains a few countries which have a fee-for-service model, what about those countries incentivized to prevent problems? Do they take new technology on faster?
- nasmorn 4y agoAustria has a single payer system but each part of that system still charges via fee for service. Innovation does not get injected top down by the omniscient insurance system but bottom up from research clinics and forward thinking doctors. People engaging the insurance directly with an efficiency play almost always fail here. There are even some vaccines against transmissible diseases that you have to pay for as an adult. I always wonder how that can make any sense. Either the value of delivering the vaccine is less than the 10 euros they are charging me (which probably means it is not very important for me to get it) or the insurance makes a colossal mistake. Especially since most vaccines are only individually unimportant since everyone else has them.
- TrackerFF 4y agoA bit unrelated - but I always thought the American concept of "annual checkups" sounded a bit weird. Here where I come from, Norway, that is not a thing - unless you have / or have had some serious illness in the past. Obviously cancer patients, or those in remission, get checked up every x months. But for regular people, it's pretty much not a thing. It also made me wonder: How much more would it cost our health-care system, if everyone took advantage of things like annual checkups, or going through those extensive screens/tests that a lot of American patients go through. I guess the fear of malpractice lawsuits, higher insurance rates, or whatever make the medical centers in US a bit more incentivized to catch anything at all. But AFAIK, we don't have any higher mortality rate here than those living in the US. Earlier this year I went to the doctor, because I was feeling a bit lethargic - turned out I had severe vitamin D deficiency. But other than that, it must be 7-8 years since I talked with a doctor. (But credit where credit is due - the US seems like an excellent option IF you really need to get treated for certain cancers. It's not like we have "death panels" or awful long wait time here, but I know patients that have gone to the US to get treatment - on their own bill - for cancers that were deemed too advanced for treatment, here in Norway.)
- paulcole 4y agoPart of the reason why it’s a thing in the US is that a huge number of people do have/have had a serious illness in the past: heart disease, diabetes, obesity, etc. Part of the reason they have those illnesses is because they neglected their health due to the cost of prevention.
- trgn 4y agoIs this really the case though? The annual check up is something that's been advocated a long time, 50s at least, and predates the obesity epidemic. The annual checkup is a symptom of a therapeutic view of health care, a view which cannot be divorced from modernism. The body is a machine which must be oiled and greased, frequently submitted to tests and expert investigation, so it can be tuned perfectly, just like a car, like a machine. This really was _the_ obsession in post war America: that all human activity (really, all of it), needed to be mediated by technology. This included personal transportation, education, cooking, ... and also maintaining our health. And that is where we are now; a chronically medicated population and a bureaucracy optimized to propagate this state of affairs. The annual checkup fits perfectly in this mindset.
- lordnacho 4y agoWe shouldn't expect outcomes to be much different, because when someone gets cancer in the rich world, they get treated with whatever medical science thinks is best. Contrast that with an ordinary purchase like a washing machine. What's left when you're definitely going to buy the Cadillac is that the price depends on how much money you have, and Americans tend to be wealthy. It also depends on factors relating to restriction of competition. If there's only so many doctors, which is the case because they restrict how many can be trained, doctors can extract more. Add to that the fear of litigation (friend dated a girl whose father made a living suing US doctors) and they end up spending money on tests that they wouldn't in the rest of the west. Possibly collective purchasing in national systems means something too, not sure.
- mlindner 4y agoThis discounts the fact that the vast amount of money spent on Medical practices is in the US which causes the advances here. Once the advances happen though they're global, so the US does not get the benefits from that money. This "tragedy of the commons" with regards to medical science causes everyone to misattribute things. Europe for example can pay little money for their medical practices because of the US bankrolling the research and drug development that allows them to do so. One route to fixing things in the US, if we really wish to do so, is to create by law a "most favored" status for the US such that if a US drug company sells outside the country, they must sell the drug in the US for the same price as the lowest price they sell it to any other country. This would largely fix our expensive healthcare, but would also harm the world heavily in advancement.
- mrtksn 4y agoDo you have the numbers to back these claims? Is the extravagant money spend on healthcare in US actually drives everything ahead? Do countries like UK, Germany, Switzerland and Japan lag behind due to the smaller amounts spent?
- mlindner 4y agoNo they don't lag behind, because as I mentioned, once they're developed the drugs are available globally, and often reverse engineered and re-sold by less scrupulous countries that don't care about intellectual property. As to your first question, I don't have an answer for you off hand.
- mrtksn 4y agoOkay, what are the sources of this claim? I'm kind of surprised that Germans and the British steal American technology developed though bankruptcy inducing childbirths. edit: Hmm, if that's true then US must be actually behind because every now and then the UK or some Europeans might invent something but the Americans won't have it because they respect intellectual property. Which means Americans will have only American stuff but the Brits and the EU will have Europeans stuff too.
- deleted 4y ago[deleted]
- lr4444lr 4y ago
- awinter-py 4y agothis 2020 paper is probably a better source Association Between Spending and Outcomes for Patients With Cancer https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994252/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994252/ ^ looks into more granular data, surveys sources that show +/0/- correlation between spending + outcomes, compares end-of-life vs non-end-of-life, cites a few studies about specific cancer types, wasteful spending. Does a better job of investigating international change in spending vs outcomes over time. the OP globocan paper is using a country average; averages don't tell you that much, esp in the US. cancer data is very granular these days (NY mandates per-case reporting, for example https://www.health.ny.gov/statistics/cancer/registry/about.htm https://www.health.ny.gov/statistics/cancer/registry/about.h...). would be interesting to have a live model somewhere of outcomes by cancer, stage, comorbidity + hospital
- auganov 4y agoHealthcare spending is almost as unequal as wealth, with a tiny minority consuming most of the resources [0]. Don't have data for this, but I see no reason not to assume a similar distribution applies to groups like cancer sufferers. That is - those most likely to die account for most of the cancer spending, while those with good outcomes account for relatively little. If you set a per person spending cap, you could expect a great reduction in per capita spending without much impact on aggregate outcomes (perhaps even an improvement). Which is exactly what public healthcare systems effectively do by strict rationing and discouraging private spending. [0] https://www.healthsystemtracker.org/chart-collection/health-expenditures-vary-across-population/ https://www.healthsystemtracker.org/chart-collection/health-...
- MauroIksem 4y agoCancer Care costs are insane..my mom is being treated for breast cancer..each chemo infusion cost $65k to her insurance company. Her surgery to remove her left breast cost $165k. 5k going to the surgeon fee while the rest was a facility fee. It's been less than a year now and the insurance has paid out almost a million dollars.
- grecy 4y agoMy Mum was diagnosed with stage 4 lung cancer - had 2.5 years of radiation, chemo and monthly doctor visits. Saw many specialists, etc. etc. Never saw a single bill, and in fact was paid actual money for the inconvenience of having to drive 3.5 hours to a bigger facility that had equipment the local small-town hospital did not. Also got a free apartment to stay in for those out of town appointments, meal allowance, etc. Mum had never paid a cent in insurance premiums in her life, etc.
- carlmr 4y ago>each chemo infusion cost $65k to her insurance company. Her surgery to remove her left breast cost $165k. 5k going to the surgeon fee while the rest was a facility fee. It's been less than a year now and the insurance has paid out almost a million dollars. Do you know that your insurance paid that, or is it what you have been quoted? US hospitals are notorious for overcharging by factors of ~10x when looking at their charge master, but the insurance companies will get a much better price after negotiating with the hospital, which is one of the reasons why the hospitals will blow-up charges in the first place, to get paid despite the insurance companies not paying everything. It's a broken system because you need an insurance agent as a "lawyer" to get the real rates. Instead what is necessary is price competition and transparency. You should be able to look up online the cost of chemotherapy for a certain type of cancer in the whole US, then you can filter by distance, reviews and price. The price on the sticker has to include everything. Whether you have insurance or not should not factor into the price at all. The free market is maybe not a solution to the social problem here, but it could at least drive down costs.
- Gatsky 4y agoThese analyses are very crude. How do they work out spending on cancer care? They take total spending and get the % spent on cancer care. % spent on cancer care is a published figure, it is not calculated directly. In single payer systems, like Australia, the true costs of cancer care are probably submerged in broader healthcare spending. The comparison is also unfair because of drug costs. Essentially, drug companies know they can make a lot on cancer drugs in the USA [1]. This means that they are more willing to negotiate lower prices in other smaller countries. There is also the fact that the crazy legislation in the USA prevents price negotiations. The USA is in a way subsidising cancer drugs for the rest of the world. I also think it is impossible to really compare cancer mortality between countries. My take on these figures is that given how big and dirty the USA is, they are doing remarkably well to have mortality that is significantly lower compared to smaller wealthy countries. [1] Fig 1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641070/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641070/